This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Guardant Health (GH) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for January 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 30th.
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Linde (LIN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.
AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
by Zacks Equity Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
by Zacks Equity Research
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
Lilly (LLY) Signs New Immunology Deal With Private Biotech
by Zacks Equity Research
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
What Makes AC Immune (ACIU) a New Buy Stock
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
by Zacks Equity Research
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
What Makes AC Immune (ACIU) a New Buy Stock
by Zacks Equity Research
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AC Immune Enters Oversold Territory
by Zacks Equity Research
AC Immune SA (ACIU) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Top Ranked Momentum Stocks to Buy for January 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 25th:
Top Ranked Momentum Stocks to Buy for January 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:
Top Ranked Momentum Stocks to Buy for January 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 22nd:
Moving Average Crossover Alert: AC Immune
by Zacks Equity Research
AC Immune SA (ACIU) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.